13F filing recap · Q4 2024
What did Patient Capital Management buy in Q4 2024?
Reported stock-position changes between this filing and the previous one.
Stock value
$2.17B
Positions
43
Estimated turnover
19.2%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Quarter in review
Patient Capital Management opened new positions in Jd.com and Apa Corporation. The firm substantially increased its stakes in Royalty Pharma, Seadrill, Biogen, Kosmos Energy, CVS Health, and Dave & Buster’s Entertainment, while dramatically adding to its Fidelity Wise Origin Bitcoin Fund and SPDR S&P 500 ETF Trust. It trimmed Expedia Group, United Airlines, Onemain Holdings, Sofi Technologies, Norwegian Cruise Line, Delta Air Lines, and Peloton Interactive, and substantially reduced Travel & Leisure, Western Alliance Bancorporation, Fiserv, and Brilliant Earth Group.